title: Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na(+) channel alpha subunit.
abstract: Mutations of amino acid residues in the inner two-thirds of the S6 segment in domain III of the rat brain type IIA Na(+) channel (G1460A to I1473A) caused periodic positive and negative shifts in the voltage dependence of activation, consistent with an alpha-helix having one face on which mutations to alanine oppose activation. Mutations in the outer one-third of the IIIS6 segment all favored activation. Mutations in the inner half of IIIS6 had strong effects on the voltage dependence of inactivation from closed states without effect on open-state inactivation. Only three mutations had strong effects on block by local anesthetics and anticonvulsants. Mutations L1465A and I1469A decreased affinity of inactivated Na(+) channels up to 8-fold for the anticonvulsant lamotrigine and its congeners 227c89, 4030w92, and 619c89 as well as for the local anesthetic etidocaine. N1466A decreased affinity of inactivated Na(+) channels for the anticonvulsant 4030w92 and etidocaine by 3- and 8-fold, respectively, but had no effect on affinity of the other tested compounds. Leu-1465, Asn-1466, and Ile-1469 are located on one side of the IIIS6 helix, and mutation of each caused a positive shift in the voltage dependence of activation. Evidently, these amino acid residues face the lumen of the pore, contribute to formation of the high-affinity receptor site for pore-blocking drugs, and are involved in voltage-dependent activation and coupling to closed-state inactivation.
authors.affiliation: Department of Pharmacology, University of Washington, Seattle, Washington 98195-7280, USA.
authors.forename: V
authors.initials: V
authors.lastname: Yarov-Yarovoy
authors.forename: J
authors.initials: J
authors.lastname: Brown
authors.forename: E M
authors.initials: EM
authors.lastname: Sharp
authors.forename: J J
authors.initials: JJ
authors.lastname: Clare
authors.forename: T
authors.initials: T
authors.lastname: Scheuer
authors.forename: W A
authors.initials: WA
authors.lastname: Catterall
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D000779:Anesthetics, Local / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D001921:Brain; D004594:Electrophysiology; D005041:Etidocaine / Q000378:metabolism / Q000494:pharmacology; D015640:Ion Channel Gating / Q000187:drug effects*; D000077213:Lamotrigine; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology; D017354:Point Mutation; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D013816:Thermodynamics; D014227:Triazines / Q000378:metabolism / Q000494:pharmacology; D014982:Xenopus laevis
chemical_list: D000779:Anesthetics, Local; D000927:Anticonvulsants; D008565:Membrane Proteins; D010879:Piperazines; D011743:Pyrimidines; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D014227:Triazines; D005041:Etidocaine; C081980:sipatrigine; D000077213:Lamotrigine